Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
about
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsAntineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicityPatient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-makingAdverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Predicting acute and persistent neuropathy associated with oxaliplatin.Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancerDose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II studyXELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials.Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuouslyIs monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trialPhase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.Resection of the Primary Tumor in Stage IV Colorectal Cancer: When Is It Necessary?Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.Management of a locally advanced rectal cancer in a patient who declined surgery.Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerA prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer.Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.Role of capecitabine in treating metastatic colorectal cancer in Chinese patients.XELOX in colorectal cancer: a convenient option for the future?Oxaliplatin: a review of approved uses.Clinical dilemmas and a review of strategies to manage drug shortages.A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?Current and advancing treatments for metastatic colorectal cancer.Combination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis.Oral versus intravenous fluoropyrimidines for colorectal cancer.
P2860
Q27028095-0DD9AA23-4951-43C5-8AC9-2B49FE1A971DQ27305830-47E7BC10-91E3-42A8-B963-B4E9C3B2C8C1Q28087212-683CEA04-4258-451B-B592-FC0C49BF2647Q33398998-B9B49286-D863-4049-B30F-30F22286F650Q33429923-F8CC11AF-49E1-4FD2-B611-DC4BB9A049F1Q33430668-DB938A9D-DD42-412D-AC74-A22FB01B22BAQ33442681-07AA1DF7-FD47-42A9-BF72-4C54CDEB8752Q33841734-4A4BDACF-3DC8-4F50-9F6A-8089F4D2C217Q33868520-49EFAFEA-9284-4E24-9441-74FF5D6283DFQ33998072-1D0D6D50-E4BF-4302-B0FA-7D426C813BF0Q34317249-9F69B9C0-4664-453F-8A82-C08D3C7B4208Q34630237-FC5C9522-4096-4EC0-85F4-731B2A8A8F16Q34639725-58D52907-18B8-4E7A-BA60-32B7735A376EQ35183695-FB5E635B-6C67-4D87-A691-DBF71C1DEC65Q35761696-CCD8F758-CB9A-45FC-B8ED-91BCDCD33DD8Q35819857-52ADBDB3-C897-4A16-9F70-03048E4CD933Q36084353-A6DE32AB-749B-4554-9BCA-CDBC3512DCE6Q36085299-C9D99BFB-ECBD-456D-AD39-1A9B1177112AQ36131174-1FA67CBA-9DEE-45F1-A174-8BB7CEF54D26Q36201465-2BB2C2C0-16AE-4B08-A933-4425261751E1Q36288022-313A3120-817A-44A5-A2E6-4B3C75979ED9Q36371089-07A186B0-BE47-4BAD-A149-0541C4C26324Q36375103-F764B07F-685F-4C61-9282-A553A48153E0Q36498946-45F2BB31-2A36-49DD-8C3B-987B3CD6B8CFQ36598736-DEC48C07-F4FD-415C-A8B0-C9368E171F9BQ36706109-3DD18096-A6C5-4FE3-A051-84F65F1A3BE4Q36778075-CF0041B6-7C99-467D-B295-8A330C22A950Q37325930-5CCE2B81-2488-41C5-A4FC-DB8A38B73207Q37471631-C8E0E5F5-B4B3-46C5-AC4C-8929B291C22FQ37560960-B31BB737-4C3C-4012-9728-912E8FBBA854Q37595951-45723736-21CA-478A-9606-3D2CFAF62F61Q37692395-7BE1E9F5-C1DC-408F-8727-AEF6A9AB917DQ37839084-98A7EF1E-64F8-45B7-A973-66153993170DQ37965616-DB4182E9-F1CB-4726-94F1-A8097443FCD3Q38095836-4B2BB279-D646-42FA-9874-BFCF01908042Q38204277-A89963F4-4820-4D11-94AB-DA3BAD9EA73AQ38216008-AA8BB778-F78C-411A-BB65-4FFC886C1023Q38628257-9E740BFE-B5C6-4DC5-9DC1-ED38259CD9C0Q38644154-06081784-22F5-42A0-89B7-D71E3ED2DF94Q38650502-CA3AB43D-206B-4C50-BC57-92E01F9C34D3
P2860
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@ast
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@en
type
label
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@ast
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@en
prefLabel
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@ast
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@en
P2093
P356
P1476
Capecitabine plus oxaliplatin ...... metastatic colorectal cancer.
@en
P2093
Antoine Adenis
Christine Rebischung
GI Group of the French Anti-Cancer Centers
Gérard Lledo
Jaafar Bennouna
Leila Kockler
Loic Bergougnoux
Michel Ducreux
Mohamed Hebbar
Roger Faroux
P2860
P304
P356
10.1002/IJC.25369
P577
2011-02-01T00:00:00Z